Nuclear magnetic resonance spectroscopy as a new approach for improvement of early diagnosis and risk stratification of prostate cancer

Prostate cancer (PCa) is the second most common male cancer worldwide and the fifth leading cause of death from cancer in men. Early detection and risk stratification is the most effective way to improve the survival of PCa patients. Current PCa biomarkers lack sufficient sensitivity and specificity...

Full description

Saved in:
Bibliographic Details
Published inJournal of Zhejiang University. B. Science Vol. 18; no. 11; pp. 921 - 933
Main Authors Yang, Bo, Liao, Guo-qiang, Wen, Xiao-fei, Chen, Wei-hua, Cheng, Sheng, Stolzenburg, Jens-Uwe, Ganzer, Roman, Neuhaus, Jochen
Format Journal Article
LanguageEnglish
Published Hangzhou Zhejiang University Press 01.11.2017
Springer Nature B.V
Subjects
Biomarkers
Biomedical and Life Sciences
Biomedicine
Cancer
Diagnostic software
Diagnostic systems
Health risks
Magnetic resonance spectroscopy
Metabolites
Metabolomics
Monitoring
NMR
Nuclear magnetic resonance
Prostate cancer
Reproducibility
Resonance
Review
Risk assessment
Sensitivity
Urine
Metabolomics
前列腺癌
Biomarker
代谢组学
生物标志物
R737.25
核磁共振(NMR)
Prostate cancer
Nuclear magnetic resonance (NMR)
Prostate cancer; Metabolomics; Nuclear magnetic resonance (NMR); Biomarker
Online AccessGet full text

Cover

More Information
Summary:Prostate cancer (PCa) is the second most common male cancer worldwide and the fifth leading cause of death from cancer in men. Early detection and risk stratification is the most effective way to improve the survival of PCa patients. Current PCa biomarkers lack sufficient sensitivity and specificity to cancer. Metabolite biomarkers are evolving as a new diagnostic tool. This review is aimed to evaluate the potential of metabolite biomarkers for early detection, risk assessment, and monitoring of PCa. Of the 154 identified publications, 27 and 38 were original papers on urine and serum metabolomics, respectively. Nuclear magnetic resonance (NMR) is a promising method for measuring concentrations of metabolites in complex samples with good reproducibility, high sensitivity, and simple sample processing. Especially urine-based NMR metabolomics has the potential to be a cost-efficient method for the early detection of PCa, risk stratification, and monitoring treatment efficacy.
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-3
content type line 23
ObjectType-Review-1
Corresponding Author
ISSN:1673-1581
1862-1783
DOI:10.1631/jzus.B1600441